The writer starts from semaglutide's 14.9% average weight loss in its main obesity trial and weighs it against what comes next.
Recap by typeshit. Post by Facebook on Facebook.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
An unsourced alert says compounded injectables, sermorelin included, face scrutiny over sterility. It names no regulator or official action.
Philstar Life has a roundup of where Eli Lilly's experimental retatrutide stands in 2026. Specifics were not available here, so tap through for the details.
Loading…